The Conversation (0)
- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Trending
Trending Articles
Trending Press Releases
Trending Companies
Silver47 Exploration
AGA:CC
Purpose Bitcoin ETF
BTCC:CA
Fidelity Advantage Bitcoin ETF
FBTC:CC
Jindalee Lithium
JLL:AU
Trending Reports
Resource
Popular Lists
Investing Ideas
Outlook Reports
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
Investing Guides
Tech
Popular Lists
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
Investing Ideas
Outlook Reports
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
Investing Guides
Life Science
Popular Lists
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
Outlook Reports
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Investing Guides
Mining Exploration Entity or Oil and Gas Exploration Entity Quarterly Cash Flow Report
April 26, 2022
Sensore (ASX:S3N) has released its quarterly cash flow.
Click here for the full ASX Release
This article includes content from SensOre , licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.
S3N:AU
22 November
NVIDIA Q3 Earnings: What Investors Need to Know
Tech giant Nvidia (NASDAQ:NVDA) surpassed analyst expectations in both revenue and earnings per share in its recently released fiscal Q3 2025 results, driven by sustained demand for artificial intelligence (AI) chips.
For the quarter ending October 27, Nvidia reported adjusted earnings per share of US$0.81, exceeding the consensus estimate of US$0.75, and revenue of US$35.08 billion, above the forecasted US$33.16 billion.
The results reflect a 94 percent year-over-year gain in revenue, though this marks a consecutive slowdown compared to the growth rates of the past three quarters.
Nvidia's fourth-quarter guidance further bolstered its performance narrative, with the company projecting revenue of US$37.5 billion, plus or minus 2 percent, slightly ahead of analysts’ expectations of US$37.08 billion.
This forecast implies a year-over-year growth rate of approximately 70 percent – still a notable deceleration compared to the prior year's 265 percent growth in the same period.
The data center segment, which accounts for the majority of Nvidia's revenue, continued to be a significant driver, generating US$30.8 billion in the quarter and exceeding analyst estimates of US$28.82 billion.
Nvidia's Chief Financial Officer, Colette Kress, also disclosed that 13,000 samples of Nvidia’s next-generation AI chip, Blackwell, had already been delivered to key customers, including Microsoft (NASDAQ:MSFT), Oracle (NYSE:ORCL) and OpenAI.
“Blackwell is now in the hands of all of our major partners, and they are working to bring up their data centers,” Kress said in an investor call reported by CNBC.
Blackwell, now in full production, is expected to contribute several billion dollars in revenue during the fourth quarter as shipments ramp up in the coming year.
The demand for the H200, Nvidia’s current-generation AI chip, also grew significantly during the last quarter, and both product lines are facing supply constraints that are expected to persist into fiscal 2026.
Meanwhile, the gaming segment remains strong with a revenue of US$3.28 billion, rising from US$2.8 billion a year earlier, as demand for GPUs for PCs, laptops and game consoles continue to increase.
The results surpassed market expectations of US$3.03 billion, marking continued strength in Nvidia’s legacy gaming business alongside its AI and data center dominance.
Smaller business segments also contributed to overall growth. Sales in the automotive segment grew 72 percent year-over-year to US$449 million, driven by increased adoption of Nvidia's chips for autonomous vehicles and robotics. Professional visualization sales reached US$486 million, up 17 percent from the prior year, signaling consistent demand for Nvidia’s enterprise solutions.
Despite the strong results, Nvidia’s stock experienced a 2 percent drop in after-hours trading after the quarterly release, raising questions among analysts and investors.
While the reasons for this decline were not immediately clear, the modest quarter-over-quarter growth implied in Nvidia’s fourth-quarter revenue forecast — at 7 percent — may have tempered enthusiasm.
However, market expectations for Nvidia, which has emerged as a dominant player in AI technology, remain exceptionally high. Shares of Nvidia have risen nearly 200 percent year-to-date, driven by investor optimism about its position in the AI landscape.
Its current valuation now exceeds that of its competitors, including Advanced Micro Devices (AMD) (NASDAQ:AMD) and Intel (NASDAQ:INTC). While Nvidia continues to lead the market, the high valuation creates pressure to consistently outperform expectations.
Nvidia also faces geopolitical and regulatory challenges that could influence its future.
A potential tariff on Taiwan-manufactured chips has sparked concerns about cost implications. Taiwan Semiconductor Manufacturing Company (TSMC) (NYSE:TSM,TPE:2330), Nvidia's primary production partner, would be directly affected by such measures, potentially impacting Nvidia's pricing and margins.
Nvidia has stated its commitment to complying with any regulations but has not detailed specific mitigation strategies.
Market reactions to Nvidia’s earnings also reflect broader uncertainties about the global semiconductor market. While demand for AI technology continues to grow, the industry remains vulnerable to macroeconomic factors, including supply chain disruptions and government policies on chip production and trade.
Looking forward, Nvidia’s management remains optimistic about its ability to meet escalating AI demand.
“The age of AI is in full steam, propelling a global shift to Nvidia computing,” said company CEO Jensen Huang in the official quarterly report.
Don't forget to follow us @INN_Technology for real-time news updates!
Securities Disclosure: I, Giann Liguid, hold no direct investment interest in any company mentioned in this article.
Keep reading...Show less
20 November
BlinkLab to Participate in the Landmark Monash University Autism/ADHD MAGNET Project
BlinkLab Limited (ASX:BB1) (“BlinkLab” or the “Company”), an innovative digital healthcare company developing smartphone-based AI powered diagnostic tests for neurological conditions, is pleased to announce their participation in the landmark MAGNET (Monash Autism & ADHD Genetics and Neurodevelopment) study conducted by Monash University’s School of Psychological Sciences.
Link: https://molecularautism.biomedcentral.com/articles/10.1186/s13229-021-00457-3.
Highlights
- The MAGNET project is an ongoing large cohort study aiming to enrol 1,000 families with children diagnosed with only autism, only ADHD, or with both autism and ADHD.
- MAGNET is utilising a novel family-based trial design where the parents, affected child and siblings (either affected or unaffected) are all enrolled in the same study.
- The aim of the study is to identify novel data-driven autism and ADHD subtypes using deep phenotyping data, including the BlinkLab Dx 1 biomarkers, that may outperform current categorical diagnoses with potential future implications for better and more personalised autism and ADHD diagnosis and treatment.
The project will help to unravel the complex symptoms of autism and Attention Deficit Hyperactivity Disorder (ADHD), and why they overlap in some children. The data generated by the study will address several limitations of categorical conceptualisations of these conditions. It is an important step towards a more dimensional understanding of their psychopathology, leading to better diagnostic models and more personalised support for children diagnosed with autism and/or ADHD. Using BlinkLab Dx 1, we aim to complete comprehensive deep sensory phenotyping of subjects with only autism, only ADHD, or with both autism and ADHD from the large MAGNET cohort.
Significance of the Study
Autism and ADHD are neurodevelopmental conditions affecting 1-4% and 5-7% of the population, respectively. Autism is characterised by deficits in social communication, restricted and repetitive patterns of behaviour and interests and altered sensory processing, whereas ADHD is defined by hyperactivity, impulsivity and inattention. In autism, 30-80% of cases exhibit ADHD symptomatology. In ADHD, 20-50% of cases exhibit autism symptoms.
The introduction of the DSM-5 has allowed, for the first time, the concurrent diagnosis of autism and ADHD and the two conditions are now recognized to co-occur in up to 50% of cases. This co-occurrence can be associated with a more severe ADHD phenotype and higher treatment needs overall. DSM-5 is a comprehensive classification system published by the American Psychiatric Association (APA). It serves as the authoritative guide used by healthcare professionals to diagnose mental disorders.
Prepulse inhibition (PPI) is a key measure used in BlinkLab Dx 1 and is considered an effective proxy for sensorimotor gating - the brain's ability to filter out irrelevant information and prioritise what is relevant. Deficits in PPI have been observed in individuals with autism but not in those with ADHD, suggesting its potential as a tool to differentiate between these two conditions. Clinically, this distinction is crucial, as treatment, support, and care strategies differ significantly for individuals with only autism, only ADHD, or with both autism and ADHD. There is also little known about the extent to which any deficits in PPI extend to the undiagnosed family members of children with autism, ADHD, or with both autism and ADHD. The diagnostic process for these neurological conditions is time-consuming and expensive and they are both characterised by significant heterogeneity in presentation. Objective behavioural markers, like PPI, potentially will play an important role in the next generation of diagnostic pathways and personalised interventions.
Dr. Henk-Jan Boele, CEO BlinkLab, commented:“Participation in the MAGNET study will enable BlinkLab to assess how its digital biomarkers, including the PPI measure, correlate with other validated behavioural, neurocognitive, neuroimaging and, potentially, genetic markers. Using these deep phenotyping and machine learning techniques, we expect to uncover novel, homogeneous data-driven clusters and subtypes of these diseases with significant future implications for better and more personalised autism and ADHD diagnosis and treatment.”
Study Design
The MAGNET study will enrol approximately 1,000 families with children aged between 4 and 18 years of age. The study will incorporate the BlinkLab PPI measure to determine how prepulse inhibition measures vary within the different diagnostic categories (i.e. ADHD vs autism vs ADHD+autism). The results will show whether BlinkLab’s Dx1 platform can distinguish between these groups. BlinkLab Dx 1 platform will be assessed alongside other validated questionnaires and biomarkers used in the MAGNET project. A unique feature of the study design is that tests will be carried out with the diagnosed child and their family members. The data from both parents (wherever possible) will determine the degree to which BlinkLab can detect performance variation within families, and thus can serve as a proxy for familial risk for these conditions.
“From the very foundation of our technology, the BlinkLab mission was always to disrupt the traditional methods of diagnosis and categorisation of psychiatric and neurodevelopmental conditions. Using more objective methods will lead to more personalised treatments and interventions. Participation in this landmark study with world- leading researchers and authorities in the field of autism and ADHD, is a testament to our mission and hard work by our team,”commented CEO of BlinkLab, Dr Henk-Jan Boele.
Click here for the full ASX Release
This article includes content from Blinklab Limited, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.
Keep reading...Show less
18 November
Large-Scale Study Validates and Enhances BlinkLab’s Accuracy in Detecting Autism in Children
BlinkLab Limited (ASX:BB1) (“BlinkLab” or the “Company”), an innovative digital healthcare company developing smartphone-based AI powered diagnostic tests for autism and other neurological conditions, is excited to announce results from the latest study in autism confirming high-accuracy in detecting autism in children ahead of upcoming FDA registrational study.
Highlights
- Analysis of a study conducted in 441 children diagnosed for autism using current standard-of-care protocols showed that ‘BlinkLab Dx 1’ detected autism with an improved sensitivity of 91% and specificity of 85%.
- These results bolster confidence that BlinkLab Dx 1 will surpass the accuracy parameters required for regulatory approval in the upcoming FDA registration trial, scheduled to commence by the end of this calendar year.
- The study is an expansion of the prior study conducted by BlinkLab, in partnership with the Turning Pointe Autism Foundation in Illinois, Princeton University, and the National Center for the Disabled in Morocco. The study was undertaken using the latest version of our digital diagnostic platform, BlinkLab Dx 1, that includes a novel set of digital biomarkers and refined machine learning models.
- This new data highlights BlinkLab Dx 1 potential as a rapid accurate test in the growing autism diagnostics market which is expected to reach $5.41 billion by 2036. A recent industry report shows families face a three-year average wait for autism assessments and 21% of U.S. clinics are unable to accept new referrals due to high demand.
About the study
A multi-center, within-subject comparison study was conducted on 441 children aged 4 to 12 years, including 285 diagnosed with autism and 156 without. This sample size far exceeded the minimum required to power the study for statistical significance.
The study was conducted in accordance with all relevant guidelines and regulations and received approval from the institutional review boards of Princeton University (#13943) and the Faculté de Médecine et de Pharmacie de Marrakech in Morocco (#23/2022).
All neurobehavioral tests were administered using the BlinkLab smartphone-based platform. Assessments included general measures of spontaneous and stimulus-evoked postural, head, facial and vocal responses, as well as specific neurometric tests like prepulse inhibition and startle habituation. Each child completed two 15-minute sessions while watching an engaging video content, with auditory stimuli delivered via headphones. During each session, computer vision algorithms tracked and recorded the position of the children’s facial landmarks over time. Analysing spontaneous and stimulus-evoked responses along with prepulse inhibition and startle habituation performance, our machine learning algorithms achieved a sensitivity of 91% and specificity of 85%. This is a substantial improvement compared to the 85% and 84%, respectively, we reported in our previous study (ASX Announcement, 2 April 2024 – BlinkLab Prospectus 2024, page 47). The BlinkLab Dx 1 model also demonstrated robust and consistent performance across gender and age groups.
The results indicate that BlinkLab’s smartphone-based testing effectively identifies sensory sensitivities in children with autism, highlighting the potential of non-invasive digital biomarkers as a diagnostic aid for autism. Additionally, they reflect the benefits of BlinkLab's institutional collaborations over the past year, which have contributed to the ongoing training and refinement of our diagnostic models.
Significance of the project
Deficits in sensory processing represent a core feature of autism, which is typically assessed through subjective observations such as questionnaires or parent-child interviews and are susceptible to geographic and socio-economic biases. An objective approach to quantify sensory sensitivity is now possible through digital neurometric evaluations. The clinical application of these sensory assessments has been confined largely to laboratory settings that use fixed equipment to provide a stable test environment making it impossible to use at scale for clinical diagnosis. This study demonstrates that fast, scientifically validated smartphone- based tests can be widely deployed in clinical settings remotely and at scale. Unlike current time-intensive and costly multidisciplinary assessments which rely on specialist expertise and are often difficult to access, BlinkLab Dx1 test offers a more efficient and accessible alternative. Current wait times for a formal autism diagnosis using standard-of-care methods often extend up to three years, with individual assessments taking as long as eight hours to complete. Studies show that these delays impose a significant economic and healthcare burden on affected families and communities.
Click here for the full ASX Release
This article includes content from Blinklab Limited, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.
Keep reading...Show less
18 November
Spectur Awarded Long Term Contract with Transport for NSW
Solar security, sensing and visual AI solutions and platforms company Spectur Limited (ASX: SP3) (Spectur or the Company) is pleased to announce the signing of a three-year contract for $787,428 with Transport for NSW (Contract No: CW2592803), with optional extensions to nine (9) years (Total price – nine year term - $2,632,284).
Highlights
- Spectur entity 3 Crowns Technologies Pty Ltd has signed a contract with Transport for NSW for the provision of cameras and analytic services.
- The value of the three-year contract is a minimum $787,428 with an optional extension of a further three plus three years for a total of 9 years (Total price $2,362,284).
- Expansion to new sites included in this contract may increase the annual contract value between $50,000 and $200,000 subject to final scope confirmation, giving a potential contract value of almost $1.4M.
- Year to date sales exceeds all previous records with $4.18m sold (13 November YTD FY25), compared with $2.205m sold October YTD in FY24.
This contract includes the provision of the following services and products:
- Live webcam vision with night vision enabled cameras for 23 existing locations including all hardware supply, installation, maintenance, software and data provisions as a managed service
- Expansion of these 23 locations to new fixed locations. This is currently being scoped
- Provision of new mobile trailer systems. Quantity to be confirmed, with the potential to increase the base contract value of $ 787,427.
The contract follows on from an ongoing smaller contract with 100%-owned entity 3 Crowns Technologies Pty Ltd (3CT), which was extended by 6 months earlier in 2024 and will be replaced when this contract is implemented, anticipated to be in January 2025. There is an optional extension of an additional three plus three years, extending the potential duration of the contract to nine years. This contract will be executed through the 3CT entity.
Key material terms of the contract are included in Appendix A.
This contract win follows on from earlier substantial contract wins with other 3CT entities in Q1, in addition to general growth within the Spectur business. Total sales (including longer term contracts) to date this financial year (at 13 November 2024) are $4.18m, a 90% increase over FY24 October YTD results of $2.205m. Whilst many of these sales are longer term contracts and have not yet converted into revenue in FY25, they underpin long term, secured recurring revenues.
Executive commentary
Spectur Managing Director, Gerard Dyson, said:
“The portion of revenue that is coming from high gross margin recurring revenue continues to increase at Spectur, with current run rates in excess of 60% of total revenue. Many of the projects that form this growing base, including the recent win with Transport for NSW, arise through the growth of existing relationships and accounts. The Spectur ecosystem is becoming increasingly flexible and expandable, with an ever greater number of opportunities to add in third party AI, sensors, cameras, devices and other applications. It is becoming a core platform for many customers, and an increasing number of resellers.
“Spectur continues to win increasingly large projects as evidenced by the year-to-date sales. This funnel of revenue continues to grow and is the product of many years of cultivation that are bearing rewards now and into the future. Ongoing strong, high margin sales, combined with recent cost control activities in response to productivity improvement, underpins the ‘fitness’ of Spectur going forward. These long- term contracts ultimately reduce and then remove the requirements for hardware sales and service to cover costs, ushering in a new era of profitability and a platform for accelerating growth.”
Click here for the full ASX Release
This article includes content from Spectur Limited, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.
Keep reading...Show less
15 November
Syntheia: Game-changing Conversational AI Solutions for the Enterprise, SMB Markets
In an industry poised to transform customer engagement, Syntheia (CSE:SYAI) is an innovative conversational AI solution addressing the complex needs of modern communication. Designed to emulate human-like conversations, Syntheia’s platform targets both large enterprises and small-to-medium businesses, which often struggle with customer support inefficiencies and high employee turnover in customer-facing roles. Syntheia offers customers an experience closer to natural human interaction focusing on language processing, tonality, sentiment analysis, and conversational behavior.
The rising demand for customer-centric interactions, the need for operational efficiency, and cost reductions that companies can realize by automating and enhancing their customer support processes lead to explosive growth in AI-driven customer service solutions.
Key TechnologySyntheia’s AssistantNLP platform is designed to handle high volumes of customer queries in multiple languages and across industries, ensuring a scalable, reliable and flexible solution for diverse customer needs. AssistantNLP is also highly accessible, structured around a freemium revenue model that allows businesses to try the service at no cost and then upgrade based on usage and additional features.
Company Highlights
- Syntheia is a conversational AI solution delivering AI-driven, human-like customer service for enterprises and SMBs.
- The AssistantNLP Platform offers 24/7/365 multilingual support, accessible globally.
- Syntheia operates on a freemium revenue model, with scalable plans catering to varied business sizes and needs.
- The conversational AI market is expected to reach $32.62 billion by 2030, with Syntheia well-positioned to capitalize on this growth.
- Syntheia’s algorithms have achieved an 84 percent success rate in data collection and 98 percent in outreach programs, highlighting exceptional efficiency.
- Financially stable, Syntheia has $2 million in cash, no debt and trades on the Canadian Securities Exchange.
This Syntheia profile is part of a paid investor education campaign.*
Click here to connect with Syntheia (CSE:SYAI) to receive an Investor Presentation
Keep reading...Show less
15 November
BlinkLab Limited (ASX: BB1) – Trading Halt
Description
The securities of BlinkLab Limited (‘BB1’) will be placed in trading halt at the request of BB1, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Wednesday, 20 November 2024 or when the announcement is released to the market.
ASX Compliance
Click here for the full ASX Release
This article includes content from Blinklab Limited, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.
Keep reading...Show less
Latest News
Latest Press Releases
Related News
TOP STOCKS
American Battery4.030.24
Aion Therapeutic0.10-0.01
Cybin Corp2.140.00
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.